Clinical trials: Oral Anticoagulants
Acute Pulmonary Embolism
Tinzaparin in the Treatment of the Acute Pulmonary Embolism
The purpose of this study is to evaluate the feasibility of the long-term treatment of pulmonary embolism with tinzaparin compared to oral anticoagulants.
- Trial name
- NCT00711308
- Testing
- tinzaparin, acenocoumarol
- Where
- 4 sites in Spain
- Volunteers
- 102 people
- Sponsor
- Complejo Hospitalario Xeral-Calde
Anticoagulation in Pregnancy
Safety And Efficacy of Low Dose Oral Anticoagulants And Aspirin Therapy
A prospective, randomized, longitudinal, open label, parallel group clinical trial was designed to compare the proportions of failure to reach INR target 2.5-3.5 with either: small dose warfarin (<5 mg/day) or phenindione (<100…
- Trial name
- NCT01758640
- Testing
- Warfarin, phenindione
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Yasser Elnahas
Pulmonary Embolism
The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics
1. Integrate pharmacokinetic-pharmacodynamic (PK-PD) modeling and pharmacogenomics techniques to develop a population PK-PD model, aiming to explore monitoring and dose guidance schemes for Direct Oral Anticoagulants (DOACs). 2.
- Trial name
- NCT06362343
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Venous Thromboembolism
Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism
Comparison of Oral anticoagulants (warfarin, apixaban and rivaroxaban) for extended VEnous Thromboembolism.
- Trial name
- COVET (NCT03196349)
- Testing
- Warfarin, Apixaban 2.5 MG, Rivaroxaban 10 MG
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Duke University
Anticoagulants and Bleeding Disorders, Atrial Fibrillation
Atrial Fibrillation Research Database
All patients with atrial fibrillation who are treated with vitamin-k antagonists (warfarin, phenprocoumon) or non vitamin K oral anticoagulants (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) in real world settings will be recorded…
- Trial name
- NCT03760874
- Where
- Italy
- Volunteers
- 5,000 people
- Sponsor
- University of Campania Luigi Vanvitelli
Coronary Artery Disease, Percutaneous Coronary Intervention
NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
The goal of this clinical trial is to compare short-term Triple Antithrombotic Therapy (DAPT + Rivaroxaban) followed by DAPT with standard DAPT in selected ACS patients with high ischemic risk.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- NCT05638867
- Testing
- Aspirin + Clopidogrel + Rivaroxaban, Aspirin + Clopidogrel
- Where
- China
- Volunteers
- 3,944 people
- Sponsor
- China National Center for Cardiovascular Diseases
Atrial Fibrillation, Ischemic Stroke
Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)
The purpose of this study is to assess safety and effectiveness of direct oral anticoagulants (DOACs) for stroke prevention in patients with non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Ischemic Stroke, Systemic Embolization, Major Bleed
- Trial name
- NCT03568916
- Testing
- Apixaban (ATC B01AF02), Dabigatran (ATC B01AE07), Rivaroxaban (ATC B01AF01)
- Where
- Canada
- Volunteers
- 227,579 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Atrial Fibrillation
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm).
- Trial name
- X-VERT (NCT01674647)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- 178 sites in United States, Belgium and 15 more
- Volunteers
- 1,504 people
- Sponsor
- Bayer
Atrial Fibrillation
Pleotropic Effect of New Oral Anticoagulants
Atrial fibrillation (AF) has been known to have several pathophysiologic mechanisms including endothelial dysfunction of heart and vessel.
- Trial name
- NCT02544932
- Testing
- dabigatran, ribaroxaban, Warfarin
- Where
- South Korea
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Kyunghee University Medical Center
Pacemaker Implantation, Pocket Hematoma and Bleeding
Pocket Haematoma Prevention in Patients Who Required Implantation/Replacement of a Pacemaker or Implantable Cardiac Defibrillator. The PHP Study.
The aim of this study is to demonstrate the efficacy of fibrin sealant (Tissucol-Baxter) in preventing pocket haematoma and subsequent complications in patients undergoing pacemaker or ICD implantation/replacement which cannot…
- Conditions
- Pacemaker Implantation, Pocket Hematoma and Bleeding, Antiplatelet Therapy or Oral Anticoagulants
- Trial name
- PHP (NCT01127984)
- Testing
- tissucol, drainage system
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Careggi Hospital
Atrial Fibrillation, Stroke
Amplatzer Amulet LAAO vs. NOAC
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for…
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Trial name
- CATALYST (NCT04226547)
- Testing
- Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Non-Vitamin K Oral Antagonists
- Where
- 127 sites in United States, Australia and 14 more
- Volunteers
- 2,650 people
- Sponsor
- Abbott Medical Devices
Venous Thromboembolism
Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement
The purpose of this study is to determine if TAK-442, once daily (QD) or twice daily (BID), is as safe and effective as enoxaparin in preventing the development of blood clots after knee replacement surgery.
- Trial name
- NCT00641732
- Testing
- TAK-442, Enoxaparin
- Where
- 64 sites in United States, Canada
- Volunteers
- 1,045 people
- Sponsor
- Takeda
Bleeding as Complication to Anticoagulation Therapy
Reporting of Adverse Events in Patients Treated With New Oral Anticoagulants
Serious adverse events in patients treated with new oral anticoagulants are underreported.
- Trial name
- NCT02107651
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Hvidovre University Hospital
Acute Major Bleeding
Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor
This is a multicentre, prospective, randomised, double-blinded, group-sequential, parallel-group, adaptive design, phase 3 study to demonstrate the haemostatic efficacy and safety of four-factor prothrombin complex concentrate…
- Trial name
- NCT04867837
- Testing
- Octaplex
- Where
- 63 sites in United States, Austria and 11 more
- Volunteers
- 100 people
- Sponsor
- Octapharma
Bleeding
A Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants (IMPACT-BLEEDING)
Prospective, cluster randomized trial including expected 168 patients with chronic use of oral anticoagulation (OAC) suffering major bleeding.
- Trial name
- NCT06575517
- Sponsor
- AstraZeneca
Atrial Fibrillation
Safe Use of New Oral Anticoagulants in Ablation for Atrial Fibrillation
Use of new oral anticoagulants (NOAC) in patients before and after catheter based pulmonary vein isolation (PVI) is still controversial.
- Trial name
- NCT02569255
- Testing
- Pulmonary venous ostia isolation
- Volunteers
- 234 people
- Sponsor
- Private Hospital Heart Center Varde
Ischemic Stroke, Intracerebral Hemorrhage
Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime
The Registry of Acute Stroke Under Novel Oral Anticoagulants-Prime (RASUNOA-Prime), an investigator-initiated study, is a German multicenter, prospective, observational registry.
- Conditions
- Ischemic Stroke, Intracerebral Hemorrhage, Oral Anticoagulation, Cardiovascular Diseases
- Trial name
- RASUNOA-Prime (NCT02533960)
- Testing
- not applicable (observational study)
- Where
- Germany
- Volunteers
- 3,832 people
- Sponsor
- University Hospital Heidelberg
Cardioembolic Stroke
Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY)
SEDMAN study is a prospective multicenter investigator initiated study (IIS). The main idea is to look by Genome Wide Association (arrays that determine more than 1 million polymorphisms) genetic risk factors associated with…
- Trial name
- SEDMAN (NCT02742480)
- Testing
- Dabigatran, Acenocoumarol
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Hospital Mutua de Terrassa
Stroke
Study of the Follow-up of Stroke Treated With Anticoagulants
Stroke is a major public health problem as it is very frequent (140,000 cases/year in France), and very serious (leading cause of death, 2nd leading cause of dementia, 3rd leading cause of handicap).
- Trial name
- AOD (NCT03292575)
- Testing
- Anticoagulants
- Where
- France
- Volunteers
- 441 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Atrial Fibrillation
This Study Observes the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) in Elderly Patients With a Heart Rhythm Disorder in Spain
This is an observational, multicenter and cross-sectional study in Non-valvular atrial fibrillation (NVAF) elderly patients currently on Non-vitamin K antagonist oral anticoagulant (NOAC) treatment for their stroke prevention.
- Trial name
- NCT03993119
- Testing
- Non-vitamin K antagonist oral anticoagulant
- Where
- 45 sites in Spain
- Volunteers
- 500 people
- Sponsor
- Boehringer Ingelheim